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The integrin CD103 is highly expressed at mucosal sites, but its role in mucosal immune 
regulation remains poorly understood. We have analyzed the functional role of CD103 in 
intestinal immune regulation using the T cell transfer model of colitis. Our results show no 
mandatory role for CD103 expression on T cells for either the development or CD4
 
 
 
CD25
 
 
 
 
regulatory T (T reg) cell–mediated control of colitis. However, wild-type CD4
 
 
 
CD25
 
 
 
 T cells 
were unable to prevent colitis in immune-deficient recipients lacking CD103, demonstrating 
a nonredundant functional role for CD103 on host cells in T reg cell–mediated intestinal 
immune regulation. Non–T cell expression of CD103 is restricted primarily to CD11c
 
high
 
MHC 
class II
 
high
 
 dendritic cells (DCs). This DC population is present at a high frequency in the gut-
associated lymphoid tissue and appears to mediate a distinct functional role. Thus, CD103
 
 
 
 
DCs, but not their CD103
 
 
 
 counterparts, promoted expression of the gut-homing receptor 
CCR9 on T cells. Conversely, CD103
 
 
 
 DCs promoted the differentiation of IFN-
 
 
 
–producing 
T cells. Collectively, these data suggest that CD103
 
 
 
 and CD103
 
 
 
 DCs represent functionally 
distinct subsets and that CD103 expression on DCs influences the balance between effector 
and regulatory T cell activity in the intestine.
 
Malfunction of regulatory circuits within the im-
mune system can lead to pathological immune
responses and tissue destruction. One example of
this is inflammatory bowel disease (IBD), which
involves chronic intestinal inflammation and
affects a substantial number of people in the
western world. A well-described mouse model
that mimics some of the features observed in
human IBD is the T cell transfer model of colitis.
Here, predominantly naive CD4
 
 
 
CD45RB
 
high
 
T cells from nonmanipulated animals are trans-
ferred into immunodeficient recipients (1, 2).
Many of the transferred T cells expand and
differentiate into Th1 cells, inducing an IBD-
like syndrome associated with severe tissue
destruction in the colon that is driven by the
enteric flora (for review see reference 3).
Although almost any leukocytic cell type can
influence the outcome of an immune response
under appropriate circumstances, an increasing
amount of data suggests that CD4
 
 
 
 T reg cells
play a central role in the control of peripheral
immune reactivity, be it against self- or nonself-
antigens (4–6). Indeed, many of the properties of
T reg cells were first established in the T cell
transfer model of colitis. Thus, the transfer of T
reg cells to recipients of CD4
 
 
 
CD45RB
 
high
 
 T
cells not only prevents colitis (2), but also cures
recipients with established disease (7). T reg
cell function in this as well as in many other
experimental systems is enriched in the natu-
rally activated CD45RB
 
low
 
CD25
 
 
 
 subset of
CD4
 
 
 
 cells (8, 9). There is evidence that both
IL-10 (10, 11) and TGF-
 
 
 
 (12) are involved in
T reg–mediated control of colitis; however, the
exact mechanisms by which these cells interfere
with pathogenic immune responses are not
completely understood.
Comparison of the gene expression profile of
CD4
 
 
 
CD25
 
 
 
 T cells with that of CD4
 
 
 
CD25
 
 
 
T cells revealed several molecules overexpressed
by the former (13, 14), raising the possibility that
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these molecules may play a role in T reg cell function.
Among the transcripts identified as being highly expressed in
CD4
 
 
 
CD25
 
 
 
 T cells was that of the integrin CD103 (
 
 
 
E
 
 inte-
grin). The corresponding molecule can be found on the cell
surface of both CD4 and CD8 T cells (15) but has also been
shown to be expressed by DCs (16–19), a principal APC pop-
ulation (20). CD103 can bind, paired with the 
 
 
 
7
 
 chain, to
E-cadherin (21). E-Cadherin is expressed on a variety of cell
types, including intestinal epithelial cells, keratinocytes, and
Langerhans cells, an epidermal APC subset (22–24). Because of
the high frequency of CD103-expressing T cells in the gut, ini-
tial hypotheses proposed that this molecule serves to facilitate
the localization of these cells in this organ. However, more re-
cent evidence not only indicates that there may be another, as
of yet unidentified ligand for CD103 (25, 26) but also shows
that T cell–expressed 
 
 
 
E
 
 
 
7
 
 is not necessary for the localization
of transgenic CD8
 
 
 
 T cells in the intestine (27).
It was previously reported that mAbs against CD103 re-
duced intestinal inflammation in IL-2–deficient animals treated
with OVA linked to 2,4,6-trinitrophenol (28), whereas an-
other study suggested that CD103 may be useful to identify
CD4
 
 
 
CD25
 
 
 
 T reg cells (29). Recently, a study by Banz et al.
indicated that the major regulatory functions observed with
CD4
 
 
 
CD25
 
 
 
 T cells may be attributed to the CD103
 
 
 
 subset
(30). Furthermore, expression of CD103 on CD4
 
 
 
CD25
 
 
 
 T
cells seems to be required for their retention at the site of 
 
Leish-
mania major
 
 infection (31). In light of these data, we decided to
investigate the contribution of CD103 to intestinal homeostasis
using the T cell transfer model of colitis. The results show that
CD103 plays an essential role in mucosal immune regulation
because T reg cell–mediated suppression of colitis was lost in
CD103-deficient recipients.
 
RESULTS
CD103 is not required for the induction of colitis by 
CD4
 
 
 
CD45RB
 
high
 
 T cells
 
The role of the 
 
 
 
E
 
 integrin, or CD103, in the localization of
T cells in the intestine is currently unclear. To investigate
the contribution of CD103 to the migration and accumula-
tion of CD4 T cells in the intestine, we transferred FACS-
sorted CD4
 
 
 
CD45RB
 
high
 
 T cells from WT or CD103-defi-
cient animals into C.B.-17-SCID recipients.
As expected, the WT population induced severe wasting
and colitis in the recipients (for examples of different degrees
of colitis, see Fig. 1), and high numbers of T cells accumu-
lated in both the intestine and peripheral lymphoid organs of
the animals (Fig. 2 A). Although the T cells did not express
CD103 at the time of transfer, at the time of death 
 
 
 
20% of
the recovered CD4
 
 
 
 T cells expressed CD103 in both the
mesenteric LN (MLN) and the lamina propria (LP) of the re-
cipients, and CD103 expression was also detected on splenic
T cells from the recipients (unpublished data). When stimu-
lated with anti-CD3 mAbs in vitro, many of the T cells iso-
lated from the LP produced IFN-
 
 
 
 (Fig. 2 B).
Transfer of the corresponding T cell population from
CD103-deficient donors yielded essentially the same results
as observed with T cells from WT donors with regard to the
Figure 1. Histopathological definition of colitis as applied through-
out this study. Animals were transferred with CD4 T cell subsets and killed 
after 8–12 wk or when reaching 80% of their initial weight. Representative 
photomicrographs show hematoxylin and eosin–stained sections of colons 
from C.B.-17-SCID recipients of CD4 T cell subsets and represent different 
definitions of colitis (none, mild, and severe). Bar, 100  m.
Figure 2. CD103 is not required for the development of colitis. 
C.B.-17-SCID mice received 4   105 sorted CD4 CD45RBhigh T cells. At 
death, hosts were analyzed for various parameters. (A) T cell numbers 
recovered from various organs. Symbols represent individual mice. Data 
are pooled from three independent experiments. The horizontal lines represent 
the mean. (B) Intracytoplasmic cytokine production by T cells from the LP 
after overnight stimulation with anti-CD3 antibodies. The numbers shown 
indicate the percentage of cells in that gate. Data are representative of 
three individual animals per group. (C) Cumulative colitis incidence in 
various recipients of CD103 /  CD4 CD45RBhigh T cells. Data are pooled 
from seven independent experiments. 
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incidence of wasting and colitis, the accumulation of T cells
in the spleen, MLN, and LP, and the production of Th1 cy-
tokines (Fig. 2). These data show that CD4 T cells need not
express CD103 in order to accumulate in the LP and induce
a Th1-mediated colitis in lymphocyte-deficient mice.
As mentioned above, CD103 is not exclusively expressed
by T cells. It was therefore possible that CD103 may play an
essential role on non–T cells for directing the accumulation of
T cells in the intestine. However, development of colitis was
similar in BALB/c-RAG
 
 
 
/
 
 
 
 or CD103
 
 
 
/
 
 
 
 BALB/c-RAG
 
 
 
/
 
 
 
hosts after WT or CD103
 
 
 
/
 
 
 
 T cell transfers, ruling out this
possibility (Fig. 2 C and Fig. S1, available at http://www.
jem.org/cgi/content/full/jem.20040662/DC1). Thus, CD103
is neither required for the accumulation of CD4
 
 
 
 T cells in
the intestine nor is it essential for the induction of colitis in
lymphocyte-deficient recipients.
 
Anti-CD103 mAb abrogates suppression of colitis by 
CD4
 
 
 
CD45RB
 
low
 
 T cells
 
Because the lack of CD103 expression on CD4 T cells does
not hamper their ability to induce colitis, it was possible that
the previously observed beneficial effect of monoclonal anti-
CD103 antibodies on the colitis development in IL-2–defi-
cient animals (28) revealed an involvement of CD103 in T
reg cell function. To test this, we transferred disease-induc-
ing CD4
 
 
 
CD45RB
 
high
 
 T cells together with protective
CD4
 
 
 
CD45RB
 
low
 
 T cells from WT donors into C.B.-17-
SCID recipients and subsequently treated the animals with a
chimeric mAb against CD103 or an isotype control. The chi-
meric antibody contained a mouse IgG1-Fc section instead of
the original rat IgG2a component, thus eliminating the possi-
bility that the antibody itself would lead to the deletion of the
cells binding it. Although the administration of anti-CD103
antibodies did not influence the development of colitis in
animals injected with CD4
 
 
 
CD45RB
 
high
 
 T cells alone
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20040662/DC1), animals receiving both CD4
 
 
 
CD45RB
 
high
 
 and CD4
 
 
 
CD45RB
 
low
 
 T cells and treated
with anti-CD103 antibodies had a significantly higher degree
of colitis as compared with the isotype-treated control group
(P 
 
  
 
0.007; Fig. 3 A). The anti-CD103–treated recipients
showed high numbers of CD4 T cells in lymphoid organs
and the LP, with a high frequency of Th1 cytokine–pro-
ducing cells in the LP of the large intestine, similar to recipi-
ents of CD4
 
 
 
CD45RB
 
high
 
 T cells alone (unpublished data).
In contrast, isotype-treated animals remained healthy
throughout the experimental period of 8–10 wk. Thus, al-
though CD103 is not essential for the disease progression, an-
Figure 3. Protection from colitis requires expression of CD103 by 
host cells. Mice received 4   105 CD4 CD45RBhigh T cells with 1 or 2   105 
CD4 CD45RBlow or CD4 CD25  T cells. (A) Colitis incidence in C.B.-17-SCID 
recipients of the indicated CD4 T cell populations. Antibodies were given i.p. 
twice weekly for 8 wk (0.5mg/injection). Data are pooled from four indepen-
dent experiments. (B) Representative CD103 expression by CD4 T cells from WT 
animals (n   8). The numbers shown indicate the percentage of cells in that 
gate. (C) Colitis incidence in C57BL/6-RAG /  recipients of CD4 CD45RBhigh 
T cells and sorted CD103  and CD103 CD4 CD25  cell subsets. Data are 
pooled from two independent experiments. (D) Cumulative colitis incidence 
in C.B.-17-SCID recipients after transfer of the indicated CD4 T cell subsets. 
Data are pooled from two independent experiments. (E) Colitis development 
in RAG /  recipients of WT CD4 T cell subsets as indicated. Data are pooled 
from five independent experiments. 
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tibodies against CD103 can abrogate suppression of colitis by
T reg cells in the CD4
 
 
 
CD45RB
 
low
 
 T cell pool.
CD103 expression by T reg cells is not essential for 
their function
Several reports showed that, in this experimental system, the
CD25  subpopulation of the CD4 CD45RBlow T cell
pool appears to contain the bulk of T reg cell activity (9,
11). Moreover, the majority of thymic and peripheral
CD4 CD103  T cells in normal animals coexpress CD25
(Fig. 3 B). Having identified that T reg cell activity requires
CD103, it was possible that this regulatory activity was con-
centrated in the CD4 CD25 CD103  subset. However, af-
ter separating splenic CD103  and CD103  subsets of natu-
rally occurring CD4 CD25  T cells and coinjecting them
with CD4 CD45RBhigh T cells into SCID recipients, there
were no obvious differences in the protective capacity of
these peripheral T cell subsets (Fig. 3 C), indicating that ex-
pression of CD103 is not a definitive marker for T reg cells.
Interestingly, the vast majority of the progeny of the trans-
ferred CD25  population expressed CD103 at the end of the
experiment irrespective of their phenotype at the time of
transfer (unpublished data), raising the possibility that
CD103 plays a role in T reg cell function after expansion in
vivo. To address this directly, the function of CD103 / 
CD4 CD25  T cells was examined. CD4 CD25  T cells
were present in a similar frequency in the spleens of
CD103 /  mice as WT controls (unpublished data) and
were able to prevent the colitis induced by either WT or
CD103 /  CD4 CD45RBhigh T cells (Fig. 3 D), demon-
strating that T cell–expressed CD103 is not essential for the
generation and maintenance of T reg cells or for their ability
to inhibit intestinal inflammation.
CD103 expression on non–T cells is essential for T reg cell 
function in vivo
The lack of any demonstrable role for CD103 on T cells in
T reg cell activity suggests that the ability of anti-CD103
mAb to abrogate T reg cell function may be an effect medi-
ated via CD103 expression on non–T cells. To test this, we
repeated the transfer experiments, this time using CD103-
deficient RAG /  recipients. Strikingly, the protection from
colitis was completely abolished when the host lacked ex-
pression of CD103 (P   0.04 when compared with BALB/
c-RAG /  recipients; Fig. 3 E). There was no evidence of
increased colitis incidence in CD103 / RAG /  recipients
of CD4 CD45RBhigh cells (Fig. S1), suggesting that
impaired T reg cell activity is not attributable to an en-
hanced colitogenic T cell response. In addition, even
CD4 CD45RBlow T cells from WT donors, when trans-
ferred on their own, led to intestinal pathology in a large
fraction of CD103 /  hosts, whereas they did not induce
colitis in BALB/c-RAG /  recipients (Fig. 3 E). This con-
firmed the reported presence of potentially pathogenic T
cells in the previously activated/memory T cell pool (32,
33). The only WT CD4  T cell population that reliably did
not induce colitis in CD103 /  hosts was the CD25  subset
(Fig. 3 E).
In conclusion, although T reg cells themselves do not re-
quire CD103 to perform their function, CD103 is mandatory
on non–T cells for the proper function of immune regulatory
activity because protection from colitis is overcome when this
molecule is absent from the host. However, the requirement
for CD103 expression on host cells is likely to be a feature of
local immune regulation rather than general CD4 CD25  T
reg cell function, as CD4 CD25  T reg cells were able to
suppress proliferation of CD4 CD25  T cells in vitro in the
presence of CD103 /  APCs (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20040662/DC1).
Non–T cell expression of CD103 is restricted to 
the CD11chigh pool
CD103 has been shown to be expressed by a variety of cell
types of hematopoietic origin but has not been found on any
nonhematopoietic cells (34). Indeed, immunofluorescent stain-
ing of colon tissue sections from unreconstituted Balb/c Rag / 
animals showed that virtually all CD103  cells costained
with  the hematopoietic cell-specific surface marker, CD45
(unpublished data). FACS analysis showed that the CD103-
expressing cells in the spleen, MLN, and colon of BALB/c-
RAG /  hosts were almost exclusively CD11chigh DCs (Fig.
4 A). Consistent with a previous study (17), further analysis re-
vealed that CD103  DCs in the spleen were B220 , Gr1low,
and expressed similarly high levels of MHC class II as their
CD103 CD11chigh counterparts (Fig. 4 B). Splenic CD103 
DCs were also CD11b , and the majority, though not all, ex-
pressed CD8  (Fig. 4 B). It was notable that splenic CD103 
DCs were larger than the CD103  subset, perhaps indicating a
more activated physiological state (Fig. 4 B). The distribution
of CD103 on DCs in the MLN and colon, though similar
to each other, differed slightly from that found in the
spleen. In both organs, populations of CD103 CD11b  and
CD103 CD8a  DCs were more prominent than in the spleen
(Fig. 4 C). CD103  DCs were present at the highest density in
the MLN, accounting for 53   6% of total CD11chigh DCs
(Fig. 4 D). In contrast, this subset represented only 28   5% of
DCs in the spleen. Enrichment of the CD103  DC subset in
the MLN and colon was more pronounced in immunocompe-
tent Balb/c mice, where CD103  DCs accounted for  10%
of DCs in the spleen (unpublished data). CD103  DCs in im-
munocompetent Balb/c mice were, however, phenotypically
similar to those in Balb/c Rag /  mice (unpublished data). In
situ analysis showed CD103  DCs in the colonic LP and in
isolated lymphoid clusters in colitic as well as protected T cell–
restored RAG /  mice (Fig. S4, available at http://www.jem.
org/cgi/content/full/jem.20040662/DC1). The latter site has
been shown to contain a high frequency of proliferating colito-
genic and T reg cells (7).
Although the CD103  DC subset appears to be pheno-
typically distinct, expression of CD103 itself is not fixed and
is dependent on external signals. By screening a panel of ac-
tivation stimuli, we found that stimulation of FACS-sortedJEM VOL. 202, October 17, 2005 1055
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CD103  DCs with anti-CD40 mAbs reduced the expression
of CD103 on these DCs. This was not caused by cell death,
as there was similar cell viability in anti-CD40 stimulated
and unstimulated CD103  DC cultures, but rather reflected
a genuine down-regulation of the CD103 molecule (Fig. 5
A and not depicted). A similar effect could also be observed
3 d after injecting the mAb into RAG-deficient animals (Fig.
5 B). Interestingly, RAG-deficient mice injected with anti-
CD40 develop a wasting disease and colitis (unpublished
data), and we found that this could not be prevented by
transfer of CD25  T cells (Fig. 5 C). Other activation stim-
uli such as LPS did not lead to the disappearance of CD103
from the cell surface (unpublished data).
Impaired T reg cell activity in CD103 / RAG /  mice
does not seem to be attributable to a gross alteration in DC
subsets, as there were similar numbers of CD11chigh DCs in
the colon, MLN, and spleen of CD103 / RAG /  as in
RAG /  mice, with no detectable changes in the CD11b 
and CD8   subsets (Fig. S5, available at http://www.jem.
org/cgi/content/full/jem.20040662/DC1). Furthermore, DCs
from both Balb/c and CD103 /  donors were able to stim-
ulate T cell proliferation equally (Fig. S5)
Functional characterization of CD103  DCs
We next investigated whether the distinct phenotypic char-
acteristics of the CD11chighMHC class IIhighCD103  cell
population corresponded with any differences in their ability
to activate T cells. DCs derived from the gut and MLN have
previously been shown to be able to support the expression
of gut-homing receptors such as CCR9 and  4 7 on T cells
(35–38).
CD11chigh cells obtained from MLN of Balb/c mice were
sorted into CD103  and CD103  subsets and cultured with
carboxyfluorescein diacetate succinimidyl ester (CFSE)–
labeled naive CD4  T cells purified from DO11.10 SCID
mice. T cells went through similar rounds of division after
Figure 4. Phenotypic characteristics of CD11chighCD103  cells. 
Spleens, MLN, or colons from BALB/c-RAG /  or WT animals were digested 
with collagenase before the distribution of cell surface molecules was inves-
tigated. (A) Representative staining of CD11c and CD103 on splenic cell 
preparations from nonreconstituted Balb/c Rag /  animals (n   4) showing 
that the majority of CD103  cells are CD11chigh. The majority of CD103  
cells in the MLN and colon were also CD11chigh. (B) Representative staining 
of various cell surface molecules on splenic preparations from nonreconsti-
tuted BALB/c-RAG /  animals (n   4). FSC, forward scatter. (C) Representa-
tive staining of CD11b, CD8 , and CD103 on MLN and colon preparations 
from nonreconstituted Balb/c Rag /  animals (n   6, pooled into three 
groups). Positioning of quadrants reflects isotype controls. The numbers 
shown in A–C indicate the percentage of cells in that gate. (D) Percentage of 
CD11chigh cells in the spleen (n   7), MLN (n   10, pooled into five groups), 
and colon (n   10, pooled into five groups) expressing CD103, as determined 
by FACS analysis. Values represent mean   SD.CD103 IN THE REGULATION OF EXPERIMENTAL COLITIS | Annacker et al. 1056
culture with either DC subset, indicating that both subsets
have a similar capacity to present antigen to T cells (unpub-
lished data). Strikingly, however, T cells cultured with
CD103  DCs were phenotypically distinct from those cul-
tured with CD103  DCs, with a much higher percentage
expressing the gut-homing chemokine receptor, CCR9, by
day 4 of culture (Fig. 6, A and B). Because the kinetics of up-
regulation of  4 7 in vitro are often slow, we also analyzed
the T cells after a further 3-d expansion in the presence of IL-2.
At this time point, the difference in CCR9 expression was
maintained, but the proportion of  4 7-expressing cells was
still similar, irrespective of which DC subset had been
present. The failure of CD103  DCs to induce CCR9 was
not caused by an inability to completely activate T cells, as a
greater proportion of T cells cultured with CD103  DCs ex-
pressed IFN-  after restimulation with anti-CD3, and this
was reflected in the levels of IFN-  in the culture superna-
tants at day 4 (Fig. 6 C and not depicted). We were unable to
detect IL-10 production by T cells, irrespective of which DC
population they were cultured with (unpublished data).
DISCUSSION
To date, the mechanisms of T reg cell function and their in-
teraction with other immune system components are incom-
pletely characterized. We have newly identified a critical
function for CD103 in the regulation of intestinal immune
responses. The data show that CD103 was not required for
the accumulation of CD4 T cells in the intestine and the in-
duction of colitis, whereas T reg cells deficient in this mole-
cule were also still able to suppress IBD. In contrast, the ab-
sence of CD103 on DCs in RAG /  hosts led to abrogation
of T reg cell activity indicating that CD103 expression by
DCs is crucial in the maintenance of a healthy balance be-
tween effector and regulatory immune cell functions. Strik-
ingly, the ability of MLN-derived DCs to imprint expression
of CCR9, a gut-homing receptor, on T cells was a unique
feature of the CD103  subset, further illustrating the impor-
tance of this DC subset in intestinal immunity.
Despite being first identified  20 yr ago (39, 40), the
function of CD103 in immune regulation has not been ex-
tensively studied. CD103 was found to be expressed by intes-
tinal intraepithelial T cells, suggesting that it was important in
the localization of CD8  T cells to epithelial surfaces (41,
42). There is also evidence that CD103 plays a functional role
in CD8  T cell responses, being required for destruction of
islet allografts (43) and for the induction of intestinal graft-
versus-host disease pathology (44). In addition, treatment
with anti-CD103 mAb ameliorated TNP-OVA–induced
colitis in IL-2–deficient mice, suggesting that CD103 may
also play a role in CD4  T cell–mediated colitis (28). How-
ever, in this study we have failed to confirm a role for CD103
in the development of colitis. Indeed, colitis developed nor-
mally in the absence of CD103 expression on colitogenic T
cells and host APCs, clearly establishing that CD103 expres-
sion is dispensable for CD4  T cell accumulation in the intes-
tine and development of Th1 cell–mediated colitis.
More recently, CD103 has been suggested to mark regu-
latory T cell subsets with enhanced T reg cell activity com-
pared with their CD103  counterparts (29, 30). CD103  T
reg cells showed an increased capacity to accumulate in in-
flammatory sites, and there is evidence that CD103 expres-
sion by CD4 CD25  T reg cells plays a functional role in
retention of T reg cells in the inflamed skin (31). However,
our findings that CD103-deficient CD4 CD25  T cells re-
tain the ability to inhibit intestinal inflammation indicate that
CD103 expression by T reg cells is not absolutely essential
for their function in vivo. The requirement for CD103 ex-
pression on T reg cells for control of skin but not intestinal
inflammation suggests that mechanisms of T reg cell–medi-
ated control are determined, at least in part, by tissue-specific
features of the inflammatory response being regulated.
Although CD103 expression may be redundant for T reg
cells themselves, it is required on innate immune cells in the
RAG /  hosts to maintain T reg cell–mediated protection
from T cell–induced colitis. CD103 expression in immune-
deficient mice is restricted primarily to a population of
CD11chighMHC class IIhigh DCs with discrete phenotypic
and functional properties. CD103  DCs are not distributed
evenly throughout secondary lymphoid tissue, with a higher
proportion present in the MLN than in the spleen. The
CD103  DC subset has a similar subset composition in the
Figure 5. Effect of stimulation through CD40 on CD103 expression. 
(A) FACS-sorted CD11chigh subpopulations were incubated overnight with 
5  g/ml anti-CD40 mAbs before assessing the expression of CD103. 
Representative stainings of two independent experiments per group. 
Further experiments with less stringently sorted CD11chigh populations gave 
similar results. (B) C57BL/6-RAG /  mice were injected i.p. with 200  g 
anti-CD40 or isotype control mAbs. 3 d later, spleens were analyzed for the 
presence of CD103  and CD11c  cells. The numbers shown indicate the per-
centage of cells in that gate. Stainings are representative of three animals 
per group. (C) Wasting disease in mice treated with anti-CD40 in the presence 
or absence of CD4 CD25  cells. Wasting was accompanied by colitis. Transfer 
of CD4 CD25  T cells 28 d before injection of anti-CD40 did not result in 
any improvement in wasting or in the severity of colitis. Data is representative 
of three similar experiments. Values represent mean   SD.JEM VOL. 202, October 17, 2005 1057
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colon as in the MLN, suggesting a link between CD103 
DCs in these two sites. Notably, Huang et al. have reported
the presence of CD103  DCs containing fragments of apop-
totic epithelial cells in the rat MLN (45). Importantly,
MLN-derived CD103  DCs but not their CD103  coun-
terparts led to the induction of the intestinal homing recep-
tor CCR9 on antigen-activated CD4  T cells. Our results
are consistent with a recent study showing that CD103
marks DCs in the MLN that have migrated from the intes-
tine and that the ability of MLN-derived DCs to imprint a
gut-homing phenotype on CD8  T cells is a unique feature
of the CD103  subset (see Johansson-Lindbom et al. on p.
1063 of this issue). In that study, induction of both CCR9
and  4 7 was restricted to CD103  DCs, whereas we found
that both CD103  and CD103  DCs from the MLN were
able to induce  4 7 expression on CD4 cells. Collectively,
these results suggest that expression of CCR9 and  4 7 is
differentially regulated on CD4 cells. Although the mecha-
nism is unknown, it may reflect quantitative differences in
the requirement for retinoic acid, which has been shown to
be responsible for the ability of gut-associated lymphoid tis-
sue (GALT)–derived DCs to imprint both CCR9 and  4 7
expression on T cells (38). Indeed, there is evidence that in-
duction of  4 7 on T cells in vitro is less dependent on the
presence of GALT-derived DCs than CCR9 (46, 47), and it
may be that other co-stimulatory pathways can contribute to
 4 7 expression on CD4 cells. Indeed, blockade of CD134–
CD134L interactions prevented the up-regulation of  4 7
expression on CD4 cells in vivo, and this latter pathway may
be involved in CD103  DC-induced  4 7 induction, par-
ticularly as expression of CD134L on in vivo–activated DCs
is restricted to the CD8   CDllb  DC subset (48), the ma-
jority of which are CD103  (Fig. 4).
Although CD103  DCs induced the expression of a gut-
homing phenotype on CD4  T cells, they were inefficient at
inducing the production of IFN-  or IL-10 by T cells. In
contrast, CD103  DCs led to the differentiation of T cells
secreting IFN-  but not IL-10. This functional difference
was not the consequence of differences in the ability of ei-
ther DC subset to activate T cells, as both induced similar
rounds of antigen-induced cell division. TGF-  has been
shown to induce CD103 expression on T cells (44, 49), and
expression of CD103 on DCs may also be a mark of their
exposure to TGF-  in the gut. Conditioning of CD103 
DCs in the immunosuppressive environment of the gut may
explain their inability to drive secretion of effector cytokines
by CD4  T cells. In fact, DCs found in the GALT appear to
be functionally distinct from their splenic counterparts and
may have a tolerogenic role under steady-state conditions
(50). Peyer’s patch DCs, for example, differed from splenic
DCs in their ability to produce high levels of IL-10 and in-
duce the differentiation of IL-4– and IL-10–producing T
cells (51). It may be advantageous, under physiologic condi-
tions, that gut-derived DCs induce T cell expression of gut-
homing receptors without differentiation into inflammatory
cytokine-secreting effector cells, preventing the develop-
ment of effector responses to gut-derived antigens. This may
change during an intestinal infection, where it will be im-
portant for effector cells to be able to home to the inflamed
intestine. In this regard it will be of interest to determine
Figure 6. Functional characteristics of CD11chigh CD103  cells. 
MACS-sorted, CFSE-labeled CD4  cells from DO11.10 SCID donors were 
incubated with FACS-sorted CD103 CD11chigh or CD103 CD11chigh DCs 
from MLN of Balb/c donors and OVA peptide. T cells were analyzed by 
FACS for expression of CCR9 and  4 7 at day 4 of culture and, after a 
further 3 d of expansion in IL-2. At day 7 of culture, T cells were restimu-
lated overnight with platebound anti-CD3 mAb before intracellular 
cytokines were assessed. (A) Mean percentage   SD of T cells expressing 
CCR9 and  4 7. Data from one of two independent experiments. (B) Repre-
sentative staining of CCR9 on T cells. (C) Mean percentage   SD of T cells 
producing IFN-  and representative stainings. Data from one of two 
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whether there are differences in the ability of CD103  DCs
isolated from the MLN of colitic mice to induce the differ-
entiation of IFN- –secreting T cells.
Impaired T reg cell activity in RAG /  mice lacking
CD103 suggests that CD103 expression not only defines func-
tionally distinct subsets of DCs but that CD103 itself plays a
functional role in regulating the balance of effector and regula-
tory responses in the intestine. DCs have been shown to play
an important role in driving CD4 CD25  T reg cell expan-
sion in vitro and in vivo. (7, 11, 52–54). During cure of colitis,
proliferating T reg cells are found adjacent to DCs in the sec-
ondary lymphoid tissue and locally in the intestine (7), suggest-
ing that DCs may also drive T reg cell expansion in tissues. In
view of this, several mechanisms can be envisaged for how
CD103 expression on DCs may modulate T reg cell function.
First, CD103, via interaction with its ligand E-cadherin, may
facilitate the retention of DCs in the intestine, influencing their
conditioning in this immunosuppressive environment. Such
“gut-conditioned” DCs may then favor regulatory as opposed
to effector cell responses, allowing CD4 CD25  T reg cells to
dominate and suppress the colitogenic effector cell response. In
the absence of CD103, gut conditioning is altered and DCs
more efficiently drive the differentiation of colitogenic Th1 re-
sponses, as is observed with the CD103  DC subset isolated
from WT mice. Alternatively, the involvement of CD103 in T
reg cell function may be indirect, involving interactions among
DCs themselves. Thus, it has been shown that ligation of
E-cadherin can inhibit DC maturation (55), raising the possi-
bility that CD103 on DCs may influence the functional state of
other DCs, leading to different T cell responses. Whatever the
mechanism by which CD103 expression on DCs effects intes-
tinal T reg cell responses, it does not appear to play a general
role in T reg cell function, as CD4 CD25  T reg cells retain
the ability to suppress T cell activation in vitro in cultures con-
taining CD103 /  APCs.
CD103 expression on DCs appears to be tightly regu-
lated, which is consistent with its important role in deter-
mining the balance between effector and regulatory T cells.
The finding that CD103 can be down-regulated via acute
CD40 stimulation provides a mechanism by which activated
CD40L  T cells may overcome suppression by T reg cells.
In support of this, CD4 CD25  T cells, although capable of
regulating the innate inflammatory response (56), could not
prevent wasting disease and colitis induced by administration
of an anti-CD40 mAb to RAG-deficient recipients, which is
consistent with the findings that T reg cell control of DC
functions can be abrogated by CD40-mediated signals (57).
In conclusion, we show that CD103, though dispensable
for T cells, is critically important in the regulation of intesti-
nal immune responses through its expression on DCs, raising
the possibility that this molecule may be a useful therapeutic
target for the treatment of IBDs.
MATERIAL AND METHODS
Mice. BALB/c, BALB/c-RAG / , CD103 /  BALB/c-RAG / ,
CD103 / , C.B.-17-SCID, C57BL/6, Ly5.1 -C57BL/6, C57BL/6-
RAG / , and DO11.10-SCID TCR-transgenic mice were maintained in
specific pathogen-free animal facilities at the University of Oxford in mi-
croisolator cages with filtered air. All genetically modified strains were ex-
tensively backcrossed onto the appropriate genetic background. Experi-
ments were performed according to the United Kingdom Animals
(Scientific Procedures) Act of 1986.
Antibodies. The following antibodies were used for cell purification: anti–
mouse CD8 (clone YTS169); MHC class II (TIB120); Mac-1 (M1/70); B220
(RA3-6B2); FITC-conjugated anti–mouse CD45RB (16A); biotinylated
anti–mouse CD25 (7D4); CyChrome-conjugated anti–mouse CD4 (RM4-
5); and PE-conjugated streptavidin. For FACS analysis, appropriately biotin-
ylated or fluorochrome-conjugated antibodies against mouse CD103 (M290),
CD3 (145-2C11), TCR-  (H57), CD25 (7D4), CD4 (RM4-5), CD11c
(HL-3), B220 (RA3-6B2), Ly-6G (Gr-1), CD11b (M1/70), CD40 (3/23),
CD80 (16-10A1), CD86 (GL-1), MHC class II (2G9), CD8  (Ly-2),  4 7
(DATK32), and CD45.2 (104) were purchased from BD Biosciences. Anti–
mouse CD40 (FGK45) was affinity purified from hybridoma supernatants.
Anti–mouse CCR9 (K629) was as described previously (58).
For in vivo use, anti–mouse CD103 (chimeric clone M290, mouse IgG1)
and an isotype control (clone 101.4) were used containing  3 endotoxin
U/mg of protein. These antibodies were obtained from Celltech R&D.
For histology, purified antibodies against CD11c (HL-3) and CD103
(M290) and an FITC-conjugated antibody against MHC class II were pur-
chased from BD Biosciences. Peroxidase-conjugated secondary antibodies
were from Jackson ImmunoResearch Laboratories.
Purification of T cell subsets. CD4 T cell subsets were isolated from
spleens as described previously (2). In brief, single cell suspensions were de-
pleted of CD8 , MHC class II , Mac-1 , and B220  cells by negative se-
lection using sheep anti–rat–coated Dynabeads (Dynal). The resulting CD4-
enriched cells were stained with anti-CD4, anti-CD25, and anti-CD45RB
or anti-CD103 mAb. Subpopulations of CD4 cells were generated by
three-color sorting on a cell sorter (MoFlo; DakoCytomation). The result-
ing populations were routinely  98% pure on reanalysis.
T cell reconstitution and antibody treatment. Recipient mice were
injected i.p. with sorted CD4 T cell subpopulations in PBS. Recipients
were aged 8–12 wk, and donors were aged 8–16 wk. If not stated other-
wise, mice received 4   105 CD4 CD45RBhigh cells alone or in combina-
tion with 1 or 2   105 cells of other CD4  subpopulations. Experiments
typically lasted between 8 and 14 wk, with mice being monitored for
changes in weight and the development of clinical signs of colitis. Chimeric
anti-CD103 mAb or isotype control mAb (1 mg) in PBS were injected i.p.
the day after T cell reconstitution. The treatment was continued with 0.5-
mg mAb injections i.p. twice weekly for 8 wk. For experiments involving
treatment with anti-CD40, immunodeficient Rag1 /  mice received 105
CD4 CD25  T cells i.p. After 28 d, these mice and an unreconstituted
control group were injected with 200  g FGK45 i.p. Mice were weighed
daily and killed after 7 d. Mice given FGK45 developed a wasting disease
and colitis characterized histologically by epithelial cell hyperplasia and a
leukocytic infiltrate within the LP (unpublished data). Transfer of
CD4 CD25  T cells did not result in any improvement in wasting or his-
tological signs of colitis.
Histology. Colons were removed from mice at death and fixed in buff-
ered 3.7% formalin. 6- m paraffin-embedded sections were cut and stained
with hematoxylin and eosin. Inflammation was scored on a scale of 0–4,
representing no (grades 0 and 1), mild (grade 2), and severe colitis (grades 3
and 4), as described previously (30).
Additional tissue samples were snap frozen and cryocut. Sections were
acetone fixed and blocked with donkey serum. Endogenous peroxidase ac-
tivity was quenched using 0.5% H2O2 and 1% sodium azide. Staining with
anti–mouse CD11c was followed with a peroxidase-conjugated anti–ham-
ster secondary and tyramide amplification. Staining with anti–mouseJEM VOL. 202, October 17, 2005 1059
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CD103 was followed with a peroxidase-conjugated anti–rat secondary and
tyramide amplification. CD103 staining was combined with staining for
MHC class II using a directly FITC-labeled antibody.
LP cell preparation and intracellular cytokine analysis. LP lympho-
cytes were purified as previously described (59). In brief, colons were cut
into 0.5–1-cm pieces and incubated in Ca- and Mg-free PBS containing
10% heat-inactivated FCS (Invitrogen) and 5 mM EDTA to remove the
epithelial layer. The remaining tissue was further digested with 100 U/ml
collagenase/dispase (Sigma-Aldrich), and the LP cells were then layered on
a Percoll gradient (GE Healthcare). The lymphocyte-enriched population
was recovered after centrifugation at 600 g for 20 min at the 40–75% inter-
face. Cells were stained for FACS analysis or for detection of cytokines and
were cultured overnight in RPMI 1640 (Invitrogen) with 10% FCS, 2 mM
L-glutamine, 0.05 mM 2-ME, and 100 U/ml each of penicillin and strepto-
mycin (RPMI complete) in 24-well flatbottom plates coated with 5  g/ml
anti–mouse CD3  (clone 145-2C11). 10  g/ml Brefeldin A (Sigma-
Aldrich) was added for the final 2–4 h of incubation, and surface and cyto-
plasmic staining was performed as described previously (60). Labeled cells
were stained with antibodies against IFN-  (XMG1.2) and TNF-  (MP6-
XT22) and analyzed on a FACSCalibur (BD Biosciences) using CellQuest
software (BD Biosciences).
Preparation of CD11chigh subsets. Pooled or single spleens or mesen-
teric LN were cut into small fragments and incubated in PBS with 10% FCS
and 1–2 mg/ml collagenase type II (Worthington Biochemicals) with 50
Kunitz U/ml DNase I (Sigma-Aldrich) for 25 min at 37 C on a shaking in-
cubator. After adding EDTA for a further 5 min, the solution was filtered
through a nylon mesh and washed in PBS with 0.1% BSA. Cells were then
stained for FACS analysis or purified for functional analysis. For the latter,
cell suspensions were incubated with an anti-FcR antibody (clone 24G2),
followed by anti-CD11c MACS beads (Miltenyi Biotec). CD11c  cells
were then positively selected on an LS MACS column. Cells were labeled
with anti-CD11c–PE, anti-CD103–biotin, and streptavidin–FITC and
sorted on a MoFlo sorter to  97% purity.
T cell differentiation assay. CD4 T cells were isolated from splenic sin-
gle cell suspensions of DO11.10-SCID mice by labeling with magnetic
anti-CD4 beads (Miltenyi Biotec) and separating the cell populations using
MACS columns according to the manufacturer’s instructions. The posi-
tively selected CD4  T cells ( 90% pure) were CFSE labeled using a Vy-
brant CFDA SE Cell Tracer Kit (Invitrogen) and resuspended in RPMI
complete. 2   105 T cells were cultured together with 105 of the sorted
CD11chigh subsets and 0.2  g/ml OVA peptide in 96-well plates for 4 d.
Cultures were supplemented with fresh medium containing recombinant
human 10 U/ml IL-2 and incubated for a further 3 d. T cells were then re-
stimulated with platebound anti-CD3 mAb and assessed for intracytoplas-
mic cytokines as described above.
Statistical analysis. Colitis scores were compared using the Mann-
Whitney U test, and differences were considered statistically significant
when P   0.05.
Online supplemental material. Fig. S1 shows similar incidence and se-
verity of CD4 CD45RBhi T cell–mediated colitis in Rag /  and CD103 / 
Rag /  recipients. Mice received 4   105 CD4 CD45RBhi T cells, and
colitis was assessed as described in Materials and methods. Fig. S2 depicts
the effect of chimeric anti-CD103 mAbs on development of colitis in recip-
ients of WT CD4 CD45RBhi T cells. Animals were treated with anti-
CD103 mAbs or isotype control mAbs throughout the experiment. Colitis
was assessed as described in Materials and methods. In Fig. S3, CD103 is not
required for T reg cell–mediated suppression in vitro. CD103 / 
CD4 CD25  T cells were cultured for 3 d with MACS-sorted
CD103 / CD4 CD25  T cells and irradiated splenocytes from WT or
CD103 /  animals. In Fig. S4, CD103  DCs are present in the LP and iso-
lated leukocytic clusters of protected and colitic mice. Representative stain-
ing for CD103 and MHC class II is shown. Double-positive cells are
CD103  DCs. Single-positive cells for CD103 are transferred T cells. Fig.
S5 depicts similar DC subset composition, distribution, and function in
Balb/c Rag /  and CD103 / Rag /  mice. In A, Cell suspensions were
prepared from spleen, MLN, and colon as described in Materials and meth-
ods and analyzed by FACS. Data are shown as the mean   SD for six mice
analyzed (pooled into three groups). In B, sections of colon from Balb/c
Rag /  and CD103 / Rag /  mice were stained with anti-CD11c and
DAPI. In C, MACS-sorted, CFSE-labeled CD4  T cells from D011.10
SCID donors were incubated with MACS-sorted CD11c  cells from the
MLN of Balb/c or CD103 /  mice and OVA peptide. T cell proliferation
was analyzed after 4 d in culture.
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